Drug Trial Radar · NCT01197534
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.
Last checked: Nov 20, 2026Latest source record: Apr 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
913
Actual
Start
Sep 2010
Primary completion
Mar 2013
Study completion Mar 2013
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 9, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not responding. The study will last for 1 year.
Conditions
- Rheumatoid Arthritis
Interventions
fostamatinibDrug
fostamatinib 100 mg twice daily
fostamatinibDrug
fostamatinib 100 mg twice daily/ 150 mg once daily
placebo, fostamatinibDrug
Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and PlaceboTime frame: 24 weeks
Locations
149 sites in 16 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Glendale, Arizona
Research Site
Mesa, Arizona
Research Site
Phoenix, Arizona
Research Site
Scottsdale, Arizona
Research Site
Tucson, Arizona
Research Site
Hot Springs, Arkansas
Research Site
Huntington Beach, California
Research Site
Torrance, California
Research Site
Trumbull, Connecticut
Research Site
Washington D.C., District of Columbia
Research Site
Boca Raton, Florida
Research Site
Brandon, Florida
Research Site
Jacksonville, Florida
Research Site
Miami, Florida
Research Site
Orlando, Florida
Research Site
Tampa, Florida
Research Site
Venice, Florida
Research Site
Zephyrhills, Florida
Research Site
Canton, Georgia
Research Site
Decatur, Georgia
Research Site
Macon, Georgia
Research Site
Boise, Idaho
Research Site
South Bend, Indiana
Research Site
Elizabethtown, Kentucky
Research Site
Crofton, Maryland
Research Site
Cumberland, Maryland
Research Site
Hagerstown, Maryland
Research Site
Kalamazoo, Michigan
Research Site
Flowood, Mississippi
Research Site
St Louis, Missouri
Research Site
Kalispell, Montana
Research Site
Omaha, Nebraska
Research Site
Manalapan, New Jersey
Research Site
Las Cruces, New Mexico
Research Site
Brooklyn, New York
Research Site
Rochester, New York
Research Site
Roslyn, New York
Research Site
Syracuse, New York
Research Site
Charlotte, North Carolina
Showing 40 of 149 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.